Generic Name and Formulations:
Bacitracin 50,000units/vial; pwd for IM inj after reconstitution.
X-GEN Pharmaceuticals, Inc
Indications for BACIIM:
Susceptible infections due to staphylococci, including pneumonia and empyema in infants.
Give by IM inj into upper outer quadrant of buttocks. Infants: <2.5kg: 900units/kg per day in 2–3 divided doses; >2.5kg: 1,000units/kg per day in 2–3 divided doses.
Renal impairment. Monitor renal function before and daily during therapy; discontinue if renal toxicity occurs. Ensure adequate hydration.
Avoid other nephrotoxic drugs (eg, aminoglycosides, polymyxin B, colistin).
Nephrotoxicity (eg, albuminuria, azotemia, cylinduria), nausea, vomiting, rash, inj site pain.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- Daily Alcohol Use May Drive Chronic Pain in Adults With HIV
- Tools to Address the Opioid Crisis
- AHA/ACC Release Updated Guidelines for Cholesterol Management
- Women Fed Soy Formula as Infants More Likely to Experience Menstrual Pain